Omalizumab is an anti-IgE monoclonal antibody that was coined to prevent asthma exacerbations in patients with severe allergic asthma. The hypothesis was tested in the EXTRA trial in which Omalizumab was added to patients with severe allergic asthma who were already on ICS and LABA therapy. The results showed 25% relative reduction in asthma exacerbations..
Category: Pulmonology - page 2
Summarized by / Author: Usama bin Nasir, MD Contribution To Literature: WARFASA trial established role of aspirin for prevention of recurrent VTE in patients who have completed 6-18 months course of anticoagulation and were no longer on it. Guidelines Adaptation According to ACCP (CHEST) Antithrombotic Therapy for VTE Disease 2016 guidelines, in patients with an unprovoked proximal..
Procalcitonin has proven to be a great marker for guiding antibiotics treatment in patients with concern for lower respiratory tract infections. However, it’s not yet established how much does clinicians adhere to using the antibiotic therapy based on procalcitonin results. The ProACT trial recently got published in NEJM. It showed that despite it’s usefulness, clinicians..